Alzheimer’s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023
DelveInsight’s, “Alzheimer’s Disease Pipeline Insights 2023” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alzheimer’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Alzheimer’s Disease Pipeline Report
- DelveInsight’s Alzheimer’s disease pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer’s disease treatment.
- The leading companies working in the Alzheimer’s disease Market include Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
- Promising Alzheimer’s disease Pipeline Therapies in the various stages of development include PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.
- November 2023: UCB Biopharma SRL announced a study of Phase 2 clinical trials for Bepranemab. The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer’s Disease (AD).
- November 2023: Alector Inc. announced a study of Phase 2 clinical trials for AL002. This is a Phase 2, randomized, parallel-group, long-term extension (LTE), dose-blind, multicenter study to evaluate the long-term safety and efficacy of AL002 in participants with Early Alzheimer’s Disease. The study is a multicenter, global trial that will enroll participants who completed the planned treatment period in AL002-2 (parent study).
- September 2023: Cassava Sciences Inc. announced a study of phase 3 clinical trials for Simufilam.The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD.
- September 2023: Alector Inc. announced a study of phase 2 clinical trials for AL002. A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer’s Disease.
Request a sample and discover the recent advances in Alzheimer’s Disease Treatment Drugs @ Alzheimer’s Disease Pipeline Outlook Report
In the Alzheimer’s disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Alzheimer’s disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Alzheimer’s Disease Overview
Dementia is a general term that refers to a decline in cognitive ability severe enough to interfere with activities of daily living. Alzheimer’s disease (AD) is the most common type of dementia, accounting for at least two-thirds of cases of dementia in people age 65 and older. Alzheimer’s disease is a neurodegenerative disease with insidious onset and progressive impairment of behavioral and cognitive functions including memory, comprehension, language, attention, reasoning, and judgment.
Find out more about Alzheimer’s Disease Treatment Landscape @ Drugs for Alzheimer’s Disease Treatment
Alzheimer’s Disease Emerging Drugs Profile
- Nilotinib: KeifeRx
- AR1001: AriBio Co., Ltd.
- LY3372689: Eli Lilly & Co
Alzheimer’s Disease Pipeline Therapeutics Assessment
There are approx. 150+ key companies which are developing the therapies for Alzheimer’s Disease. The Alzheimer’s Disease companies which have their Alzheimer’s Disease drug candidates in the most advanced stage, i.e. phase III include, KeifeRx.
DelveInsight’s Alzheimer’s Disease pipeline report covers around 160+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Alzheimer’s Disease Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Alzheimer’s Disease Pipeline Therapies @ Alzheimer’s Disease Clinical Trials Assessment
Scope of the Alzheimer’s Disease Pipeline Report
- Coverage- Global
- Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Alzheimer’s Disease Companies- Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
- Alzheimer’s disease Pipeline Therapies- PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.
Dive deep into rich insights for new drugs for Alzheimer’s Disease Treatment, Visit @ Alzheimer’s Disease Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Alzheimer’s Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Alzheimer’s Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Nilotinib: Novartis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LY3372689: Eli Lilly & Co.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Alzheimer’s Disease Key Companies
- Alzheimer’s Disease Key Products
- Alzheimer’s Disease- Unmet Needs
- Alzheimer’s Disease- Market Drivers and Barriers
- Alzheimer’s Disease- Future Perspectives and Conclusion
- Alzheimer’s Disease Analyst Views
- Alzheimer’s Disease Key Companies
- Appendix
For further information on the Alzheimer’s Disease Pipeline Therapeutics, reach out @ Alzheimer’s Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market
